Bio-Pharm
SK Biopharm’s Epilepsy Drug ‘Xcopri’ Wins Korean Approval
SK Biopharm’s Epilepsy Drug ‘Xcopri,’ with ₩400 Billion ($290 Million) Annual U.S. Sales, Wins Korean Approval SK Biopharm’s…